bioRxiv Science⌕ Search

Biology subjects

Bartuzi, D.

Publications and source records attributed to Bartuzi, D..

2 recordsLinked to original sources

Structural Dynamics of the Dopamine D2 Receptor with a Non-Basic Ligand

Progress in understanding protein-ligand interactions is revolutionizing drug design, especially for G protein-coupled receptors (GPCRs), which are targets for 35% of marketed drugs.1 The dopamine D2 receptor (D2R) represents a key drug target in schizophrenia and Parkinsons disease.2 While structural studies have clarified its interactions with classical ligands, the behavior of atypical, non-basic ligands like D2AAK2 remains unclear. Notably, D2AAK2 shows strong selectivity for D2R over the closely related D3R, despite identical binding pocket composition. Here, we present a cryo-EM structure of D2AAK2 bound to D2R, showing that aspartate 3.32 serves as the main anchoring point, even though the compound lacks a basic nitrogen atom. Using enhanced sampling molecular dynamics simulations and experimental approaches, we uncover a complex binding energy landscape. Simulations suggest that D2AAK2 receptor subtype selectivity between identical binding sites arises from different energy barriers for their conformational changes. Non-basic ligands offer advantages such as better brain penetration and improved pharmacokinetics.3,4 This study provides the first structural insights into a non-basic ligand targeting D2R, paving the way for developing more effective, selective drugs.

pharmacology and toxicology↗

Structure-guided allosteric modulation of the delta opioid receptor

Opioid analgesics remain essential for pain management but are associated with significant adverse effects, including respiratory depression, tolerance, and dependence. The {delta}-opioid receptor ({delta}OR) represents a promising therapeutic target for developing safer opioid analgesics with reduced adverse effects compared to conventional -opioid receptor-targeting drugs. Positive allosteric modulators (PAMs) offer advantages over direct agonists by enhancing endogenous opioid signaling while preserving natural spatiotemporal activation patterns, potentially avoiding tolerance and dependence issues. Here, we present high-resolution cryo-EM structures of {delta}OR complexed with the peptide agonist DADLE and the PAM MIPS3614, revealing a novel lipid-facing allosteric binding site formed by transmembrane helices 2, 3, and 4. MIPS3614 stabilizes the active receptor conformation through a critical hydrogen bond with residue N1313.35 in the conserved sodium binding site, a key regulatory region controlling GPCR activation. Comprehensive mutagenesis, molecular dynamics simulations, and structure-activity relationships validate this proposed mechanism. Structure-guided optimization yielded MIPS3983 with enhanced binding affinity and retained cooperativity. Our findings establish the first molecular framework for {delta}OR allosteric modulation and provide a structural foundation for the rational design of safer opioid therapeutics.

pharmacology and toxicology↗